CPRX News and Press, Catalyst Pharmaceuticals Inc. From 08/10/22

Gainers: OraSure Technologies ( OSUR ) +28% . BioAtla ( BCAB ) +24% . Catalyst Pharmaceuticals ( CPRX ) +16% . Clovis Oncology ( CLVS ) +13% . Quanterix ( QTRX ) +13% . Losers: Singular Genomics Systems ( OMIC ...

Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.28 beats by $0.11 . Revenue of $53.11M (+46.0% Y/Y) beats by $4.03M . The Company continues to forecast that its full year 2022 total revenues will be in the range of between $1...

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights...

CORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

88% technical buy signals. 16 new highs and up 49.40% in the last month. 78.74% gain in the last year. Price targets as high as $15.00. The Barchart Chart of the Day belongs to the BioPharma company Catalyst Pharmaceuticals (CPRX). I found the sto...

Catalyst Pharmaceuticals ( NASDAQ: CPRX ) said it settled a patent infringement litigation with Jacobus Pharmaceuticals and PantherRx Rare related to their marketing of Ruzurgi, a version of the Catalyst's autoimmune disorder therapy Firdapse. Catalyst's Firdap...

CORAL GABLES, Fla., July 12, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

It's no secret that investors flock to biotech stocks for exposure to moonshot returns. For instance, if you invested in Catalyst Pharmaceuticals (NASDAQ: CPRX) around five years ago, you are sitting with a gain of about 239% compared to the market's total return of near 87%. Th...

BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...

Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase reflected steady growth for its drug Firdapse, to treat pediatric patients with ...